Please ensure Javascript is enabled for purposes of website accessibility

Why Orphazyme Stock Skyrocketed 24.6% Today

By Keith Speights - Jun 23, 2021 at 4:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Goldman Sachs upped its stake in the drugmaker -- but only briefly.

What happened

Shares of Orphazyme (ORPH) skyrocketed 24.6% as of the market close on Wednesday after rising as much as 56.6% earlier in the day. The big gain came after the drugmaker announced that Goldman Sachs (GS 0.84%) temporarily increased its stake to 5.58% on Jun. 16, 2021, but then reduced its position to less than 5% the following day. 

So what

What does the "major shareholder announcement" made by Orphazyme today mean for investors? Pretty much nothing.

$1 bill folded into an arrow pointing up.

Image source: Getty Images.

It would be one thing if a major investment firm like Goldman Sachs had materially increased its position in Orphazyme and held on to the shares. That could have at least hinted that the small drugmaker's prospects were improving. However, in this case, Goldman Sachs' move was only temporary.

More importantly, Goldman Sachs briefly increased its stake in Orphazyme before the announcement on Jun. 18 that the U.S. Food and Drug Administration (FDA) didn't approve arimoclomol in treating rare disease Niemann-Pick Disease Type C (NPC). This FDA rejection was a huge setback for Orphazyme and caused the biotech stock to plunge last week.

Now what

Orphazyme still hopes to win European approval for arimoclomol in early 2022. The company is also evaluating a potential path to still move forward with seeking FDA approval for the experimental drug. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Orphazyme A/S Stock Quote
Orphazyme A/S
The Goldman Sachs Group, Inc. Stock Quote
The Goldman Sachs Group, Inc.
$334.67 (0.84%) $2.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.